A study in south-west Nigeria found that high-sensitivity C-reactive protein was more consistently associated with obesity than tumour necrosis factor-alpha or interleukin-6 in adults with type 2 diabetes.
A study from south-west Nigeria suggests that high-sensitivity C-reactive protein, better known as hs-CRP, may be a more dependable blood marker of obesity-related inflammation in adults with type 2 diabetes than two other widely studied immune signals. Published in BMC Endocrine Disorders, the research compared hs-CRP with tumour necrosis factor-alpha and interleukin-6 in 151 people with type 2 diabetes and 100 healthy controls matched for age and sex. The main finding was clear: all three markers were higher in the diabetes group, but hs-CRP was the one that remained most consistently linked with obesity once other factors were taken into account.
The work matters because evidence on the inflammatory biology of obesity and diabetes has come mainly from studies in North America, Europe and parts of Asia. Researchers in sub-Saharan Africa have had far less data to work with, even though local populations face additional complications that can distort inflammatory measurements. In Nigeria, one important example is asymptomatic malaria, which can raise immune markers even when a person has no obvious illness. The authors therefore screened participants for malaria and adjusted for infection status, alongside age, sex and medication use, in an effort to isolate the relationship between inflammation and excess body weight more accurately.
The study was cross-sectional, meaning it captured information at a single point in time rather than following people over months or years. Blood levels of the three markers were measured with enzyme-linked immunosorbent assay, a laboratory method commonly used to detect proteins with precision. Obesity was defined using the standard body mass index threshold of 30 or above, while abdominal fat was assessed with waist measurements. According to the paper, hs-CRP showed the strongest links with both body mass index and waist size, and the results were statistically robust even after the researchers accounted for the skewed distribution typical of inflammatory data.
The most telling result came when all three markers were tested together in the same model. hs-CRP retained its association with obesity, while the effects of tumour necrosis factor-alpha and interleukin-6 weakened. That pattern fits with the biology of inflammation: the two cytokines tend to fluctuate quickly, while hs-CRP is produced by the liver in response to inflammatory signalling and gives a steadier read-out of chronic low-grade inflammation. The paper also notes that the findings were similar after the data were log-transformed, a standard step used to reduce the influence of extreme values in skewed biomarker datasets.
The authors are cautious about the limits of their work. Nearly all of the participants with diabetes were taking metformin, a drug known to affect both weight and inflammation, which made it difficult to separate the medication’s effect from the disease itself. Statin use was also considered, but the study could not address issues such as dose, duration or adherence. Because the design was cross-sectional, it cannot show whether inflammation is driving obesity, obesity is driving inflammation, or both are part of the same underlying process. Even so, the study adds to a growing body of evidence that hs-CRP may be useful as a practical and inexpensive marker of obesity-related risk in people with type 2 diabetes, particularly in settings where locally grounded data have been scarce.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
